SRNE News and Press, Sorrento Therapeutics Inc. From 10/22/20

Sorrento Therapeutics (NASDAQ: SRNE) is one of this year's rollercoaster stocks, riding the market crash and the coronavirus product hype train to grow by more than 450% before collapsing to its present level, 130% above its price on Jan. 1. Sorrento's stock is extremely headline-dr...

Sorrento Therapeutics (NASDAQ: SRNE) has jumped completely into the COVID-19 arena with tests, treatments, and vaccines against the novel coronavirus. In this Fool Live video, Healthcare and Cannabis Bureau Chief Corinne Cardina and longtime Motley Fool contributor Brian Or...

The stock market has been resilient during a tumultuous 2020 (the S&P 500 is up about 7% since January), but as many people have personally experienced this year, that performance doesn't tell the whole story of the U.S. economy. One-third of Americans say they dipped into their sav...

Sorrento Therapeutics (NASDAQ: SRNE) ended the week on a down note, tumbling by nearly 11% on Friday on news of a fresh acquisition. Sorrento revealed in a regulatory filing that it has agreed, through a subsidiary, to purchase ACEA Therapeutics. Sorrento's initial payment is $3...

Are These The Best Biotech Stocks To Buy Right Now? One of the hottest investment themes in the stock market this year centered around biotech stocks . If you combine the words “biotech” and “small-cap” together, that could be a great recipe for b...

Abivertinib, one of Sorrento Therapeutics ' (NASDAQ: SRNE) COVID-19 drug candidates, will be entering phase 2 testing in Brazil. This follows approval granted on Wednesday by the National Health Surveillance Agency (ANVISA), the country's healthcare regulator, which has cleared the ...

This article presents a list of stocks with the highest short interest as a percentage of shares outstanding. An unprecedented year amid the COVID-19 pandemic driving historic volatility has represented significant trading opportunities for short-sellers. We analyze key trends and...

Sorrento's ([[SRNE]] -13.2%) stock shows weakness, as investors appear to be disappointed at the company's COVID-19 pipeline and R&D update yesterday, as some shareholders seemingly had high hopes on announcement of groundbreaking news, at this highly anticipated event.While Sorrento...

Gainers: Interpace Biosciences (IDXG) +41%.Allscripts Healthcare Solutions (MDRX) +31%.Replimune Group (REPL) +27%.VOXX International (VOXX) +25%.AnaptysBio (ANAB) +22%.NIO (NIO) +20%.OncoCyte (OCX) +20%.Panhandle Oil and Gas (PHX) +16%.RealNetworks (RNWK) +14%.Oblong (OBLG) +13%.Losers:...

Sorrento Therapeutics (NASDAQ: SRNE) , a clinical-stage biotech with an extensive COVID-19 product pipeline, is having a rough day today. The biotech's stock is down by a noteworthy 14% as of 10:54 a.m. EDT Wednesday. The culprit? Investors appear to be disappointed at Sorrento'...